Harry Hamlyn, MD
Psychiatry · Rapid City, SDNPI 1801997739
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$848
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$561
- Otsuka America Pharmaceutical, Inc.$505
- Teva Pharmaceuticals USA, Inc.$343
- Axsome Therapeutics, Inc.$325
- Johnson & Johnson$317
- plus $2K from 14 others
What the payments were for
- Food & beverage$4,77799%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,000
- LYBALVI$465
- ARISTADA INITIO$250
- NUEDEXTA$227
- UZEDY$125
- AUSTEDO$125
- INGREZZA$125
- CAPLYTA$125
- COBENFY$125
- ABILIFY MAINTENA$124
- ABILIFY ASIMTUFII$124
- Auvelity$123
- REXULTI$113
- Wakix$112
How this compares
$4,842 in reported general payments places this provider in the 90th percentile of 79 psychiatry providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 25 | $189,606 |
| AustedoDeutetrabenazine | 12 | $118,718 |
| Invega SustennaPaliperidone Palmitate | 37 | $116,611 |
| VraylarCariprazine Hcl | 42 | $66,937 |
| RexultiBrexpiprazole | 46 | $52,701 |
| BelsomraSuvorexant | 57 | $25,175 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $20,539 |
| Paliperidone ErPaliperidone | 47 | $14,780 |
| TrintellixVortioxetine Hydrobromide | 20 | $14,518 |
| Aripiprazole | 265 | $11,468 |
| Clozapine | 94 | $11,455 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $10,462 |
| Atomoxetine Hcl | 94 | $8,824 |
| EliquisApixaban | 28 | $8,762 |
| Olanzapine | 259 | $7,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $245 | $189,60625 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $343 | $118,71812 claims |
| Johnson & JohnsonInvega Sustenna | $317 | $116,61137 claims |
| AbbVieVraylar | $158 | $66,93742 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $505 | $52,70146 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $238 | $24,98042 claims |
| Alkermes, Inc.Lybalvi | $848 | $20,53913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 psychiatry providers in South Dakota.
Other psychiatry in Rapid City
- Mark GarryRapid City$1K
- Stephen ManloveRapid City$490
- Kyle SiefersRapid City$368
- Richard RenkaRapid City$314
- Charles LordRapid City$290
- Kirsten ButzRapid City$157
- Paul FrazerRapid City$127
- James ChiuSioux Falls$1.7M
- Hari KannanSioux Falls$913K
- Rajesh SinghSioux Falls$393K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.